The effect of zinc supplementation on glucose homeostasis: a randomised double-blind placebo-controlled trial
Authors:
- John R. AttiaJAJohn R. Attia
- Elizabeth HollidayEHElizabeth Holliday
- Natasha WeaverNWNatasha Weaver
- Roseanne PeelRPRoseanne Peel
- Alexis HureAHAlexis Hure
- John WiggersJWJohn Wiggers
- Mark McEvoyMark McEvoy
- Andrew SearlesASAndrew Searles
- Penny ReevesPRPenny Reeves
- Priyanga RanasinghePRPriyanga Ranasinghe
- Ranil JayawardenaRJRanil Jayawardena
Open Access
- 22 April 2022
- journal article
- research article
- Published by Springer Nature in Acta Diabetologica
- Vol. 59 (7) , 965-975
Abstract
Aims: The burden and health costs of Type 2 Diabetes Mellitus continue to increase globally and prevention strategies in at-risk people need to be explored. Previous work, in both animal models and humans, supports the role of zinc in improving glucose homeostasis. We, therefore, aimed to test the effectiveness of zinc supplementation on glycaemic control in pre-diabetic adults. Methods: We conducted a randomized, double-blind, placebo-controlled trial across 10 General Practitioner (GP) practices in NSW, Australia. The trial is known as Zinc in Preventing the Progression of pre-Diabetes (ZIPPeD)Study. Pre-diabetic (haemoglobin A1c [HbA1c] 5.7–6.4%, 39–46 mmol/mol) men and women (N = 98) were all assigned to a free state government telephone health coaching service (New South Wales Get Healthy Information and Coaching Service) and then randomised to either daily 30 mg zinc gluconate or placebo. Blood tests were collected at baseline, 1, 6 and 12 months for the primary outcomes (HbA1c, fasting blood glucose (FBG)); secondary outcomes included Homeostasis Model Assessment 2 (HOMA 2) parameters, lipids, body weight, height, waist circumference, blood pressure and pulse. Results: The baseline-adjusted mean group difference at 6 months, expressed as treatment–placebo, (95% CI) was −0.02 (−0.14, 0.11, p = 0.78) for HbA1c and 0.17 (−0.07, 0.42; p = 0.17) for FBG, neither of which were statistically significant. There were also no significant differences between groups in any of the secondary outcomes. Zinc was well tolerated, and compliance was high (88%). Conclusion: We believe our results are consistent with other Western clinical trial studies and do not support the use of supplemental zinc in populations with a Western diet. There may still be a role for supplemental zinc in the developing world where diets may be zinc deficient. Trial registration: Australian and New Zealand Clinical Trials Registry, ACTRN12618001120268. Registered on 6 July 2018.Keywords
Funding Information
- NSW Ministry of Health (G18/31636)
- Blackmores Limited
- The University of Newcastle
This publication has 32 references indexed in Scilit:
- Is dietary zinc protective for type 2 diabetes? Results from the Australian longitudinal study on women’s healthBMC Endocrine Disorders, 2013
- Effects of zinc supplementation on diabetes mellitus: a systematic review and meta-analysisDiabetology & Metabolic Syndrome, 2012
- Characteristics of participants in Australia's Get Healthy telephone-based lifestyle information and coaching service: reaching disadvantaged communities and those most at needHealth Education Research, 2011
- Role of Zinc in Human Islet Amyloid Polypeptide AggregationJournal of the American Chemical Society, 2010
- Zinc and diabetes — clinical links and molecular mechanismsThe Journal of Nutritional Biochemistry, 2009
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Impaired Fasting Glucose and Impaired Glucose ToleranceDiabetes Care, 2007
- A genome-wide association study identifies novel risk loci for type 2 diabetesNature, 2007
- Oral administration of a zinc complex improves type 2 diabetes and metabolic syndromesBiochemical and Biophysical Research Communications, 2006
- Intracellular Transport of Proinsulin in Pancreatic β-CellsJournal of Biological Chemistry, 1995